ISDIN, S.A., a pharmaceutical company, researches, develops, and distributes various solutions for dermatology conditions and related needs. The company provides solutions for baby care, dry skin, oral health, greasy skin and dandruff, women health, skin care, atopic skin, hair loss, acne, psoriasis, hygiene, mycosis, bacterial infections, dermatitis, hydric deficit, and photosensitivity needs. It offers fusion fluids, gel cream dry touch products, oil free sunscreen compact make-up products, pediatrics gel creams, fusion gels, lotion sprays, anti-wrinkle creams, actinic keratosis and non-melanoma skin cancer prevention creams, body hydration and hygiene products, facial hydration creams, an...
Founded in 1975
Mayne Pharma Group Ltd Signs SUBACAP Distribution Agreements with ISDIN and Glenmark
Aug 9 13
Mayne Pharma Group Ltd. has signed two marketing and distribution agreements with ISDIN and Glenmark for SUBACAP, an improved formulation of itraconazole used to treat fungal infections. The execution of these agreements follows an extensive search and selection process for partners that have the infrastructure, knowhow and track record to successfully commercialise SUBACAP. ISDIN will market the product in Spain, Italy and Portugal. Glenmark will market the product in the United Kingdom. Under the two exclusive distribution agreements, Mayne Pharm will receive upfront payments, milestone payments upon meeting certain market launch hurdles, and a percentage of net sales in each country. Mayne Pharma will manufacture the product for both distributors at its facility in South Australia. Product launch is expected to occur by the end of calendar 2013 in the UK, early 2014 for Spain and by the end of 2014 for Italy and Portugal following a 'repeat use' procedure to extend the existing marketing authorisation into those additional countries.